Revolution Medicines Inc
Research Revolution Medicines Inc (RVMD) on Bullrun: market cap USD 41.55B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRVMD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 41.55B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 644.37M
- Free cash flow-USD 745.31M
Valuation Snapshot
latest market cap is USD 41.55B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 1.13B | -USD 913.73M | n/a | -5.95 | USD 383.75M | USD 158.70M | USD 1.63B |
| FY2024 | USD 0 | -USD 600.00M | -USD 567.74M | n/a | -3.58 | USD 543.06M | USD 135.84M | USD 2.27B |
| FY2023 | USD 11.58M | -USD 436.00M | -USD 358.30M | n/a | -3.86 | USD 696.15M | USD 87.94M | USD 1.83B |
| FY2022 | USD 35.38M | -USD 249.00M | -USD 235.22M | n/a | -3.08 | USD 161.41M | USD 64.21M | USD 685.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 41.55B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.69B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.13B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.70B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.11B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.87B | n/a | n/a | n/a |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
ETFs that hold Revolution Medicines Inc
Revolution Medicines Inc is one of the ten largest holdings of 10 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 2.88% | 0.35% |
| Invesco NASDAQ Next Generation 100 UCITS ETF Acc | 2.22% | 0.25% |
| JPM BetaBuilders US Small Cap Equity UCITS ETF - USD (acc) | 0.52% | 0.13% |
| HAN-GINS Tech Megatrend Equal | 1.27% | 0.59% |
| Harbor Health Care UCITS ETF - Accumulating | 4.43% | 0.89% |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 2.88% | 0.35% |
| Vanguard FTSE Global Small-Cap UCITS ETF - USD Acc | 0.37% | 0.22% |
| Vanguard FTSE Global Small-Cap UCITS ETF USD Dist | 0.37% | 0.22% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Revolution Medicines Inc's market cap?
Revolution Medicines Inc's market capitalization is USD 41.55B.
What does Revolution Medicines Inc do?
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.